Cara Therapeutics Reports Clinical Updates - On track to report topline data for KALM-2 Phase 3 global trial of KORSUVA Injection in second quarter - - On track to complete interim statistical analysis for ongoing Phase

Therapeutics Reports Clinical Updates

On track to report topline data for KALM-2 Phase 3 global trial of KORSUVA Injection in second quarter -

On track to complete interim statistical analysis for ongoing Phase 2 trial of Oral KORSUVA in atopic dermatitis in second quarter

Timeline to submit KORSUVA Injection New Drug Application to FDA in second half of 2020 remains unchanged -

Conn., March 25, 2020 - Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical company focused on developing

and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors,

or KORs, today announced that it is on track to report topline data in the second quarter of 2020 from its ongoing pivotal KALM-2

Phase 3 global trial of KORSUVA Injection in hemodialysis patients with moderate-to-severe chronic kidney disease-associated

pruritus (CKD-aP). The Company also plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA)

for KORSUVA Injection in the second half of 2020.

the ongoing situation with COVID-19, and in accordance with the FDA's updated guidance for conducting clinical trials, we

are pleased that we remain in-line with our timetable to report topline data from KALM-2 in the second quarter," said Derek

Chalmers, Ph.D., D.Sc., President and Chief Executive Officer of Cara Therapeutics. "We continue to make significant progress

across our entire Phase 3 program for KORSUVA Injection, including supportive safety studies, and still expect to submit our NDA

in the second half of this year."

is also currently evaluating Oral KORSUVA in two ongoing Phase 2 trials for atopic dermatitis (AD) patients with

moderate-to-severe pruritus and patients with pruritus and hepatic impairment due to primary biliary cholangitis (PBC),

respectively. As previously announced, the Company expects to complete an interim statistical analysis for the ongoing Phase

2 trial in AD patients in the second quarter of this year. In addition, data from the previously reported positive Phase 2

dose-ranging trial of Oral KORSUVA for the treatment of pruritus in patients with moderate-to-severe CKD will be presented as

a late-breaker oral virtual presentation at the National Kidney Foundation Spring Clinical Meeting on March 26,

the KALM-2 Phase 3 Trial

is a Phase 3, global, multicenter, randomized, double-blind, placebo-controlled, 12-week trial (with a 52-week open label extension

phase) designed to evaluate the safety and efficacy of 0.5 mcg/kg KORSUVA (CR845/difelikefalin) Injection in 430 hemodialysis

patients with moderate-to-severe pruritus.

primary efficacy endpoint is the proportion of patients achieving at least a 3 point improvement from baseline in the weekly

mean of the daily 24 hour Worst Itching Intensity Numeric Rating Scale (WI-NRS) score at week 12. Secondary endpoints include

assessment of the proportion of patients achieving >4-point improvement from baseline in weekly mean of the daily 24-hour WI-NRS

score at week 12 as well as itch-related quality of life changes measured using the validated self-assessment 5-D itch and Skindex-10

pivotal KALM-1 Phase 3 US trial is complete and topline data were reported in May 2019. The trial met the primary endpoint, with

a statistically significant improvement in the proportion of patients on KORSUVA Injection achieving a 3-point or greater improvement

in the mean WI-NRS score versus placebo (p=0.000019). The trial also met all secondary endpoints and KORSUVA Injection was generally

well-tolerated through 12 weeks of treatment with a safety profile consistent with prior clinical trials.

Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities

designed to alleviate pruritus by selectively targeting peripheral KORs. Cara is developing a novel and proprietary class of

product candidates, led by KORSUVA (CR845/difelikefalin), a first-in-class KOR agonist that targets KORs located in the

peripheral nervous system and on immune cells. In the Company's KALM-1 Phase 3 trial and two Phase 2 trials, KORSUVA

(CR845/difelikefalin) Injection has demonstrated statistically significant reductions in itch intensity and concomitant

improvement in pruritus-related quality of life measures in hemodialysis patients with moderate-to-severe CKD-aP and is

currently being investigated in Phase 3 trials in hemodialysis patients with CKD-aP. Oral KORSUVA is in Phase 2 trials for

the treatment of pruritus in patients with CKD, AD and PBC.

FDA has conditionally accepted KORSUVA as the trade name for difelikefalin injection. CR845/difelikefalin is an investigational

drug product and its safety and efficacy have not been fully evaluated by any regulatory authority.

contained in this press release regarding matters that are not historical facts are "forward-looking statements"

within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of these forward-looking statements

include statements concerning the ongoing trials and future development of the Company's product candidates, including

the timing for completion and reporting of topline results of Cara's KALM-2 Phase 3 clinical trial and the timing of

the interim statistical analysis for its Phase 2 clinical trial for atopic dermatitis, the timing for submission of an NDA

for KORSUVA Injection, the impacts on these clinical and regulatory timelines of the COVID-19 pandemic, and the potential for

KORSUVA to be a therapeutic option for pruritus or atopic dermatitis. Because such statements are subject to risks and

uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks

are described more fully in Cara's filings with the Securities and Exchange Commission, including the "Risk

Factors" section of Cara's Annual Report on Form 10-K for the year ended December 31, 2019 and its other

documents subsequently filed with or furnished to the Securities and Exchange Commission. All forward-looking statements

contained in this press release speak only as of the date on which they were made. Except to the extent required by law, Cara

undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on

which they were made.

Investor Relations, Inc.